Efficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma: A single‐arm clinical trial

Ähnliche Einträge

• Toripalimab plus concurrent chemoradiotherapy for recurrent nasopharyngeal carcinoma: A single‐arm, phase 2 clinical trial
  von: Zhehao Xiao, et al.
  Veröffentlicht: (2026)
• Comparison of ≥2 lines immunotherapy regimens for recurrent/metastatic nasopharyngeal carcinoma
  von: Lan Peng, et al.
  Veröffentlicht: (2026)
• Optimizing treatment for platinum‐resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab
  von: Yasunori Yoshino, et al.
  Veröffentlicht: (2025)
• A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer
  von: Gayle S. Jameson, et al.
  Veröffentlicht: (2026)
• A study protocol for an open‐label, single‐arm, single‐center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma
  von: Huiying Huang, et al.
  Veröffentlicht: (2024)